ECTRIMS 2019: Monitoring disease activity in MS using serum neurofilament light protein

Jan Lycke | ECTRIMS 2019 | Septttember 13, 2019

Föreläsare: Jan Lycke

Determination of Neurofilament light in blood may improve the assessment of patients and should be considered as part of No Evidence of Disease Activity. In this MEDtalk Jan Lycke talks about that Neurofilament light (NFL) has the potential to become the first soluble biomarker to monitor disease activity and treatment response in clinical practice of MS.